Board
Changes
- Appointment of Colin Bond,
a highly experienced Board member and Audit Committee Chair with
extensive international CDMO and biopharma expertise
- Appointment made as part of
OXB's Board succession planning
Oxford, UK - 18
November 2024: OXB (LSE: OXB),
a quality and innovation-led cell and gene therapy CDMO, today
announces the appointment of Colin Bond as a Non-Executive Director
effective 1 January 2025. Mr. Bond will also join the Audit
Committee as part of succession planning ahead of Stuart Henderson
losing his independent status as a Non-Executive Director in June
2025.
Colin Bond has a wealth of
international experience in the CDMO and biopharma industries and
was most recently Chief Financial Officer of Sandoz listed on the
SIX Swiss Exchange, where he played a key role in the company's
successful spin-off from Novartis. Prior to Sandoz, Mr. Bond was
Chief Financial Officer of Vifor Pharma and Evotec.
He also served as Chair of the Audit
Committee for Siegfried AG, a leading CDMO quoted on the
SIX Swiss Exchange, for ten years until May 2023. He is
currently Chair of the Audit Committee of BioPharma
Credit PLC on the London Stock Exchange and a member of
the Supervisory Board
of Formycon AG.
During his early career, Mr. Bond
worked as a pharmacist, auditor and management consultant for
Procter & Gamble, Arthur Andersen and PwC. Mr. Bond
is a Fellow of the Institute of Chartered
Accountants in England and Wales and a
Member of the Royal Pharmaceutical Society of Great Britain. He
holds a BSc in Pharmacy from Aston University and an MBA from
London Business School.
Additionally, OXB announces that
Leone Patterson has informed the Board of her decision to step down
as a Non-Executive Director on 31 December 2024 in order to focus
on her new responsibilities following her recent appointment as
Chief Business and Financial Officer of Zymeworks.
Dr.
Roch Doliveux, Chair of OXB, commented: "Colin is a highly
strategic operator with extensive international CDMO and healthcare
sector expertise plus first-rate technical accounting credentials.
He is well regarded by the investment community and has overseen
organisations that have undergone significant growth and
transformation. On behalf of the Board, I am delighted to welcome
Colin to OXB and thoroughly look forward to working with him. I
would also like to thank Leone for her sharp analytical insights
and active contributions to OXB during her tenure on the Board and
wish her the very best with her new
responsibilities."
Colin Bond, incoming Board member at OXB,
said: "OXB's position as a leader in cell and gene
therapy manufacturing, combined with its innovative approach and
strong client partnerships, presents a compelling opportunity that
I have recently watched with interest. I am excited to join the
Board at this important time and look forward to working with the
team to support OXB's continued growth and success in enabling the
delivery of life-changing therapies to patients
worldwide."
Relevant disclosures
Save as disclosed, there are no
disclosures required to be made in accordance with UKLR
6.4.8(R).
-Ends-
Enquiries:
OXB:
Sophia Bolhassan, Head of Investor
Relations - T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology
companies, providing viral vector development and
manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class
capabilities span from early stage development to
commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods
and depth of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer
and packaging cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing
facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on LinkedIn
and YouTube.
